Edition:
United Kingdom

Anavex Life Sciences Corp (AVXL.OQ)

AVXL.OQ on NASDAQ Stock Exchange Capital Market

2.73USD
5:17pm BST
Change (% chg)

$0.07 (+2.63%)
Prev Close
$2.66
Open
$2.66
Day's High
$2.74
Day's Low
$2.66
Volume
5,272
Avg. Vol
123,526
52-wk High
$5.14
52-wk Low
$1.86

Latest Key Developments (Source: Significant Developments)

Anavex Life Sciences Q3 Loss Per Share $0.06
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Anavex Life Sciences Corp ::ANAVEX LIFE SCIENCES REPORTS FISCAL THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.06.Q3 EARNINGS PER SHARE VIEW $-0.10 -- THOMSON REUTERS I/B/E/S.CASH AND EQUIVALENTS OF $25.8 MILLION AT JUNE 30, 2018.  Full Article

Anavex Receives Approval To Initiate Phase 2b/3 Clinical Trial Of Anavex®2-73
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Anavex Life Sciences Corp ::ANAVEX LIFE SCIENCES RECEIVES APPROVAL TO INITIATE PHASE 2B/3 CLINICAL TRIAL OF ANAVEX®2-73 FOR THE TREATMENT OF EARLY ALZHEIMER’S DISEASE.ANAVEX LIFE SCIENCES RECEIVES APPROVAL TO INITIATE PHASE 2B/3 CLINICAL TRIAL OF ANAVEX®2-73 FOR THE TREATMENT OF EARLY ALZHEIMER’S DISEASE.ANAVEX LIFE - RECEIVED APPROVAL BY AUSTRALIAN HUMAN RESEARCH ETHICS COMMITTEE TO INITIATE PHASE 2B/3 48-WEEK SAFETY AND EFFICACY TRIAL OF ANAVEX®2-73.  Full Article

Anavex Life Sciences reports PK and PD data from Phase 2a trial of ANAVEX2-73
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Anavex Life Sciences Corp :Anavex Life Sciences reports PK and PD data from Phase 2a trial of ANAVEX2-73 in mild-to-moderate Alzheimer’s Disease patients.Anavex Life Sciences Corp - ‍ANAVEX2-73 demonstrates desirable PK/PD properties.Anavex Life Sciences Corp - ‍clear concentration-effect relationship between ANAVEX2-73 and study measurements​.  Full Article

Anavex signs material transfer agreement with Biogen
Wednesday, 28 Sep 2016 

Anavex Life Sciences :Signed material transfer agreement with Biogen under which Biogen will test Anavex's lead drug candidate, Anavex 2-73.  Full Article

Anavex Life Sciences says drug shows efficacy to support disease modification in Parkinson’s disease
Thursday, 22 Sep 2016 

Anavex Life Sciences Corp : Significant improvements were seen on all measures: behavioral, histopathological, and neuroinflammatory endpoints . Data indicates that ANAVEX 2-73 is well tolerated .Anavex life sciences’ drug shows efficacy to support potential disease modification in Parkinson’s disease.  Full Article

BRIEF-Anavex Life Sciences Reports Q2 Loss Per Share Of $0.11

* ANAVEX LIFE SCIENCES REPORTS FISCAL SECOND QUARTER 2018 FINANCIAL RESULTS